Lead Product(s): Semaglutide
Therapeutic Area: Nutrition and Weight Loss Product Name: Ozempic
Highest Development Status: Phase III Product Type: Peptide
Partner/Sponsor/Collaborator: Novo Nordisk
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 02, 2021
The recent STEP 1 trial showing the beneficial impact of diabetes drug semaglutide on weight could be a game-changer in helping many people with obesity to lose a significant amount of weight.